Novo Nordisk A/S (NONOF)
| Previous close | 135.15 |
| Open | 134.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 132.00 - 134.50 |
| 52-week range | 74.70 - 140.32 |
| Volume | |
| Avg. volume | 28,311 |
| Market cap | 591.039B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 45.66 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.86 (1.38%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
- Zacks
Play These New ETFs to Tap Lucrative Weight Loss Drug Market
Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.
- Reuters
Eli Lilly's diabetes drug tirzepatide gets approval in China
SHANGHAI (Reuters) -Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market. Novo Nordisk's popular diabetes drug Ozempic won approval from China in 2021 and the company saw sales of the weekly injection in the greater China region that includes Hong Kong and Taiwan double to 4.8 billion Danish Krone ($698 million) last year. Eli Lilly did not say when sales would begin in China or how many doses would be supplied.
- Barrons.com
Hims & Hers Stock Spikes. It’s Taking on Big Pharma With Cheap Obesity Shots.
A relatively small telehealth company that recently went public wants to take a slice of the big pharmaceuticals companies’ hottest market. Hims & Hers Health said on Monday that it is offering weight-loss injections for as low as $199 a month, a move that capitalizes on the growing demand for such treatments. The telehealth platform started offering oral medication kits for weight loss late last year and is now expanding its roster of products as it seeks to compete with companies like Eli Lilly and Novo Nordisk.
